Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 31, 2013

Intrexon Wraps Up Busy Month with Three Collaborations and an Acquisition

  • Agilis Biotherapeutics has become the third company this month to partner with Intrexon to gain access to its synthetic biology technologies to advance product development. In a deal announced today, Agilis and Intrexon will focus on developing innovative DNA-based therapeutics to treat Friedreich's ataxia (FRDA).

    Previous collaborations announced earlier this month focused on better hair and skin (a partnership with Johnson & Johnson Innovation and J&J Consumer & Personal Products Worldwide) and infertility (a partnership with OvaScience to improve in vitro fertilization).

    Agilis will utilize Intrexon's UltraVector® platform and RheoSwitch Therapeutic System® (RTS®) to develop gene therapies and genetically modified cell therapies. The partners planned approach to target FRDA will employ RTS®, an inducible gene switch technology that regulates the expression of therapeutic proteins or bioactive RNA in a dose-dependent fashion.

    The ultimate goal of this collaboration is to develop therapeutics to repair or replace the "broken" gene in FRDA and enable increased production of the frataxin protein to alleviate the downstream effects of frataxin deficiency, according to the firms. Agilis also has an option to advance a second undisclosed rare disease indication.

    Earlier this month, Intrexon acquired Medistem for $26 million.


Related content

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »